In recent years, sodium-glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists (MRAs) have drawn attention as promising treatments for CKD, with many studies demonstrating their renal and cardiovascular benefits [26, 39–41]. The gene discussed is SLC5A2; the disease is chronic kidney disease.